Tandem Diabetes Care (Nasdaq:TNDM) announced today that real-world data supports its t:slim X2 insulin pump with Control-IQ technology.
Data from the ongoing real-world Control-IQ observational (CLIO) study demonstrating immediate and sustained benefits in a diverse cohort of participants was presented at the American Diabetes Association (ADA) 82nd Scientific Sessions in New Orleans.
Get the full story at our sister site, Drug Delivery Business News.
Tandem Diabetes Care (Nasdaq:TNDM) shares slid slightly after hours today on first-quarter results that were mixed compared to the consensus forecast.
The San Diego-based automated insulin delivery technology developer posted losses of $14.7 million, or 23¢ per share, on sales of $175.9 million for the three months ended March 31, 2022, for a bottom-line slide deeper into the red despite sales growth of 24.7%.
Losses per share of 23¢ for Tandem came in 16¢ behind projections on Wall Street, where analysts were looking for sales of $168.43 million.
Get the full story at our sister site, Drug Delivery Business News.
All kinds of technologies were on display at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona last week.
From continuous glucose monitoring (CGM) to automated insulin delivery, with plenty in between, a number of companies shared positive data for their diabetes offerings.
Here are five of the biggest stories to come out of ATTD 2022:
Dexcom’s G7 is accurate in pediatric T1D patients
Dexcom (Nasdaq:DXCM) published new data highlighting the accuracy of the next-generation G7 continuous glucose monitor in children.
The study, published in the Journal of Diabetes and Scientific Technology, evaluated the G7 CGM in children and adolescents with type 1 diabetes. G7, which last month won CE mark approval, remains under FDA 510(k) review.
Get the full story at our sister site, Drug Delivery Business News.
Tandem Diabetes Care (Nasdaq:TNDM) announced real-world data confirming positive outcomes with its t:slim X2 insulin pump.
Data demonstrated that the t:slim X2 pump with Control-IQ advanced hybrid closed-loop technology resulted in immediate and ongoing improvements in glycemic control, quality of life outcomes and user-reported reduced burden of diabetes management.
Get the full story at our sister site, Drug Delivery Business News.
Change is continuous in continuous glucose monitoring (GCM), with expanded wear-times, improved accuracy and more. Meanwhile, never-ending innovation in insulin delivery is delivering wearable patches and closedloop delivery systems, making insulin management easier for people with diabetes.
Expectations were already high for new technology coming out of the diabetes space, and significant improvements last year only lifted those hopes higher. Let’s check in with a few companies promising big steps forward, including some that have already made significant progress.
Get the full story at our sister site, Drug Delivery Business News.
Change is continuous in continuous glucose monitoring (GCM), with expanded wear-times, improved accuracy and more. Meanwhile, never-ending innovation in insulin delivery is delivering wearable patches and closedloop delivery systems, making insulin management easier for people with diabetes.
Expectations were already high for new technology coming out of the diabetes space, and significant improvements last year only lifted those hopes higher. Let’s check in with a few companies promising big steps forward, including some that have already made significant progress.
Get the full story at our sister site, Drug Delivery Business News.
Tandem Diabetes Care (Nasdaq:TNDM) issued an urgent field safety notice in Europe for its t:slim X2 insulin pump with Basal-IQ technology.
The notice, dated February 2022, alerts users of Tandem’s insulin pump with a software version of 6.3.0.1 that there may be a potential safety risk when using the pump within its normal specifications. Tandem’s t:slim X2 with Control-IQ technology is not affected.
Get the full story at our sister site, Drug Delivery Business News.
Tandem Diabetes Care (NASDAQ:TNDM) shares were slightly up on fourth-quarter results that beat the consensus revenue forecast.
The San Diego-based company posted profits of $10.8 million, or 16¢ per share, on sales of $210 million for the three months ended Dec. 31, 2021, for a 36.4% bottom-line slide on sales growth of 24.9%.
Get the full story at our sister site, Drug Delivery Business News.
Tandem Diabetes Care (NASDAQ:TNDM) today announced FDA clearance of bolus insulin dosing on the t:slim X2 insulin pump using the t:connect mobile app.
Company officials boasted that the t:connect mobile app is now the first smartphone app FDA-cleared for insulin delivery on both the iOS and Android operating systems.
Tandem Diabetes Care plans to roll out the mobile bolus feature update in the U.S. throughout the spring in a series of limited launch groups that it has already selected. The company plans an expanded launch later this summer.
Get the full story on our sister site Drug Delivery Business News.
Automated insulin delivery technology developer Tandem Diabetes Care (NSDQ:TNDM) announced that it made new appointments in three executive leadership positions.
San Diego-based Tandem named Rick Carpenter as CTO, Libba Sapitsky as SVP of Customer Care and Rizwan Pervez as SVP of Quality and Regulatory.
Get the full story at our sister site, Drug Delivery Business News.
Tandem Diabetes Care (NSDQ:TNDM) shares took a massive hit after hours today on third-quarter results that beat the consensus forecast.
TNDM shares were down 12.3% at $124.01 per share after the markets closed. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the day down 0.1%.
Get the full story at our sister site, Drug Delivery Business News.
Tandem Diabetes Care (NSDQ:TNDM) shares ticked up after hours today on second-quarter results that came in well ahead of the consensus forecast.
The San Diego-based company posted profits of $4 million on sales of $172.1 million for the three months ended June 30, 2021, for a massive bottom-line gain from losses of -$27.1 million this time last year on sales growth of 57.6%.
Get the full story at our sister site, Drug Delivery Business News.